C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
260/206, 167/211
C07D 457/12 (2006.01) A61K 31/48 (2006.01) A61K 31/535 (2006.01) C07D 457/04 (2006.01) C07D 457/06 (2006.01)
Patent
CA 1319684
Abstract of the Disclosure Ergolinyl compounds which are nitrogen- substituted in the 8-position and have Formula (I) Image (I) and physiologically compatible salts thereof, wherein (a) R1 is hydrogen and the 8-substituent can be in the .alpha.- or .beta.-position; (i) when Image represents a double bond, R2 is hydrogen, C1-4-alkyl or C1-7-acyl, R3 is hydrogen, chlorine or bromine, and R4 is C1-6-alkyl, C3-6-cycloalkyl-C1-3-alkyl, C3-6-alkenyl, or C3-6-alkynyl or (ii) when the bond Image represents a single bond R2 and R are as defined above, and R is C4 6-alkyl, C3 6 cycloalkyl-C1-3-alkyl, C3-6-alkenyl, or C3-6-alkynyl; or (b) R1 is -?-NR5R6, and the 8-substituent can be in the .alpha.- or .beta.-position, Image represents a single or double bond, R2, R3 are as defined above, R4 is C2-6-alkyl, C3-6- cycloalkyl-C1-3-alkyl, C3-6-alkenyl, or C3-6-alkynyl; and R5 is hydrogen, C1-10 alkyl, C3-10-alkenyl, or C3-10-alkynyl, is C1-10 alkyl C3-10-alkenyl, C3-10-alkynyl, or aryl or R5 and R6 together with the connecting N-atom form a 5- to 10-membered hetero- cyclic ring, preferably 5- or 6-membered, which optionally can contain further heteroatoms. The compounds of this invention are distinguished, e.g., as shown in animal experiments, by higher efficacy, longer duration of activity, and lower acute toxicity. The compounds predominantly affect central dopa- mine receptors, on which they can act in an agonistic and/or antagonistic fashion. The direct dopaminergic effectiveness of the compounds shows them to be valuable compounds for the treatment of dopamine deficiency conditions of the central nervous system, for example, for treatment of parkinsonism, certain forms of dementia, and in hyperprolactinemia. Be- cause of the preferential stimulation of certain dopamine receptor subpopulations, dopaminergic routes of the cen- tral nervious system can be influences selectively, thus lessening the risk of undasirable side effects.
418299
Eder Ulrich
Haffer Gregor
Lorenz Hans-Peter
Sauer Gerhard
Schneider Herbert
Marks & Clerk
Schering Aktiengesellschaft
LandOfFree
Ergolinyl compounds nitrogen-substituted in the 8- position,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ergolinyl compounds nitrogen-substituted in the 8- position,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ergolinyl compounds nitrogen-substituted in the 8- position,... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1273285